Beactica Therapeutics is a specialist drug discovery and development company, committed to the fight against cancer. Beactica is advancing a proprietary pipeline of first-in-class therapeutics by applying its molecular interaction-based drug discovery engine synergistically across multiple small molecule modalities – including allosteric modulators, protein–protein interaction inhibitors and targeted protein degraders (PROTACs).